
Saxenda
Liraglutide
- SKU
- 0169-2800
- Mfr
- Novo Nordisk Pharmaceutical Industries, LP
$1,762.99
Price for one pack
Prescription required. Upload your prescription at checkout or email it to us after ordering. We ship once a pharmacist has checked it. How it works
SAXENDA is indicated in combination with a reduced calorie diet and increased physical activity to reduce excess body weight and maintain weight reduction long term in: • Adults and pediatric patients aged 12 years and older with body weight greater than 60 kg and obesity.
- Strength
- Liraglutide 6 mg/mL
- Unit of measure
- Per mL
- Dosage form
- Injection, Solution
- Route
- Subcutaneous
Pharmacologic class
- GLP-1 Receptor AgonistEstablished class
- Glucagon-Like Peptide 1Chemical structure
- Glucagon-like Peptide-1 (GLP-1) AgonistsMechanism
- Brand name
- Saxenda
- Generic name
- Liraglutide
- Manufacturer
- Novo Nordisk Pharmaceutical Industries, LP
- Product NDC (SKU)
- 0169-2800
- Active ingredients
- Liraglutide 6 mg/mL
- Unit of measure
- Per mL
- Dosage form
- Injection, Solution
- Route
- Subcutaneous
- DEA schedule
- Not controlled
- Product type
- HUMAN PRESCRIPTION DRUG
- Marketing category
- NDA
- Application number
- NDA206321
- Marketed since
- December 31, 2014
- Label revised
- February 25, 2026
| Package NDC | Description |
|---|---|
| 0169-2800-15 | 5 SYRINGE, PLASTIC in 1 CARTON (0169-2800-15) / 3 mL in 1 SYRINGE, PLASTIC |
| 0169-2800-90 | 1 SYRINGE, PLASTIC in 1 CARTON (0169-2800-90) / 3 mL in 1 SYRINGE, PLASTIC |
| 0169-2800-97 | 1 SYRINGE, PLASTIC in 1 CARTON (0169-2800-97) / 3 mL in 1 SYRINGE, PLASTIC |
Reading this NDC
0169-2800-15
- 01Labeler code
- Novo Nordisk Pharmaceutical Industries, LP
- 02Product code
- Saxenda, injection, solution
- 03Package code
- 5 syringe, plastic in 1 carton (0169-2800-15) / 3 ml in 1 syringe, plastic
Liraglutide is an acylated human GLP-1 receptor agonist with 97% amino acid sequence homology to endogenous human GLP-1(7-37). Like endogenous GLP-1, liraglutide binds to and activates the GLP-1 receptor, a cell-surface receptor coupled to adenylyl cyclase activation through the stimulatory G-protein, Gs. Endogenous GLP-1 has a half-life of 1.5 to 2 minutes due to degradation by the ubiquitous endogenous enzymes, dipeptidyl peptidase 4 (DPP-4) and neutral endopeptidases (NEP).
Unlike native GLP-1, liraglutide is stable against metabolic degradation by both peptidases and has a plasma half-life of 13 hours after subcutaneous administration. The pharmacokinetic profile of liraglutide, which makes it suitable for once-daily administration, is a result of self-association that delays absorption, plasma protein binding, and stability against metabolic degradation by DPP-4 and NEP. GLP-1 is a physiological regulator of appetite and calorie intake, and the GLP-1 receptor is present in several areas of the brain involved in appetite regulation.
In animal studies, peripheral administration of liraglutide resulted in the presence of liraglutide in specific brain regions regulating appetite, including the hypothalamus. Although liraglutide activated neurons in brain regions known to regulate appetite, specific brain regions mediating the effects of liraglutide on appetite were not identified in rats.
Warning: Risk of thyroid c-cell tumors
- Liraglutide causes dose-dependent and treatment-duration-dependent thyroid C-cell tumors at clinically relevant exposures in both genders of rats and mice. It is unknown whether SAXENDA causes thyroid C-cell tumors, including medullary thyroid carcinoma (MTC), in humans, as the human relevance of liraglutide-induced rodent thyroid C-cell tumors has not been determined.
- SAXENDA is contraindicated in patients with a personal or family history of MTC and in patients with Multiple Endocrine Neoplasia syndrome type 2 (MEN 2). Counsel patients regarding the potential risk of MTC with use of SAXENDA and inform them of symptoms of thyroid tumors (e.g., a mass in the neck, dysphagia, dyspnea, persistent hoarseness). Routine monitoring of serum calcitonin or using thyroid ultrasound is of uncertain value for early detection of MTC in patients treated with SAXENDA. WARNING: RISK OF THYROID C-CELL TUMORS See full prescribing information for complete boxed warning.
- Liraglutide causes thyroid C-cell tumors at clinically relevant exposures in both genders of rats and mice. It is unknown whether SAXENDA causes thyroid C-cell tumors, including medullary thyroid carcinoma (MTC), in humans, as the human relevance of liraglutide-induced rodent thyroid C-cell tumors has not been determined.
- SAXENDA is contraindicated in patients with a personal or family history of MTC or in patients with Multiple Endocrine Neoplasia syndrome type 2 (MEN 2). Counsel patients regarding the potential risk of MTC and the symptoms of thyroid tumors.
SAXENDA is indicated in combination with a reduced calorie diet and increased physical activity to reduce excess body weight and maintain weight reduction long term in:
- Adults and pediatric patients aged 12 years and older with body weight greater than 60 kg and obesity.
- Adults with overweight in the presence of at least one weight-related comorbid condition. Limitations of Use
- SAXENDA contains liraglutide. Coadministration with other liraglutide-containing products or with any other glucagon-like peptide-1 (GLP-1) receptor agonist is not recommended.
- The safety and effectiveness of SAXENDA in pediatric patients with type 2 diabetes have not been established. SAXENDA is a glucagon like peptide 1 (GLP-1) receptor agonist indicated in combination with a reduced calorie diet and increased physical activity to reduce excess body weight and maintain weight reduction long term in:
- Adults and pediatric patients aged 12 years and older with body weight greater than 60 kg and obesity.
- Adults with overweight in the presence of at least one weight-related comorbid condition.
Limitations of Use:
- Coadministration with other liraglutide-containing products or with any other GLP-1 receptor agonist is not recommended.
- The safety and effectiveness of SAXENDA in pediatric patients with type 2 diabetes have not been established.
Read before you order

Weight management · 3 min read
How GLP-1 weight-loss medicines work
Semaglutide, tirzepatide and liraglutide explained: how they reduce appetite, how quickly they work and what to expect in the first months.

Weight management · 2 min read
Managing nausea and other GLP-1 side effects
Practical ways to cope with nausea, constipation and reflux on semaglutide or tirzepatide, and the warning signs that need a doctor.

Weight management · 2 min read
Orlistat, phentermine and Contrave: the older weight-loss medicines
How orlistat, phentermine and naltrexone-bupropion work, who they suit and the side effects to know about before starting.
More in Weight Management
View all
Brand · Capsule
Alli
Orlistat 60 mg/1
- SKU
- 0135-0461
- Mfr
- Haleon US Holdings LLC
From $47.99Min. 7 packs

Brand · Capsule
Alli
Orlistat 60 mg/1
- SKU
- 71610-805
- Mfr
- Aphena Pharma Solutions - Tennessee, LLC
From $1,329.43

Brand · Tablet
Contrave Extended-Release
Naltrexone Hydrochloride 8 mg/1, Bupropion Hydrochloride 90 mg/1
- SKU
- 51267-890
- Mfr
- Nalpropion Pharmaceuticals LLC
From $199.00Min. 2 packs

Brand · Injection
Mounjaro
Tirzepatide 4.17 mg/mL
- SKU
- 0002-4052
- Mfr
- Eli Lilly and Company
From $1,454.99